-
Innovation Ranking
NewInnovation Ranking – HCL Technologies Ltd
HCL Technologies Ltd (HCL) is a provider of software and IT infrastructure services. The company offers a range of solutions in IT infrastructure management services, digital process operations, cloud native services, cybersecurity services, digital and analytics services, DRYiCE, IoT works, HCL software services, SIAM/XaaS products & advanced services, industry software services and engineering and R&D services. HCL offers its services to financial services, manufacturing, telecom, retail and consumer packaged goods services, media and entertainment, life sciences, insurance services, capital markets...
-
Company Insights
Innovation and Patenting activity of HCL Technologies Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HCL Technologies Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
NewIT Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the cloud, data analytics, and future of work themes lead the thematic screen of GlobalData’s IT services sector scorecard. This is dominated by the global IT services giants Accenture, IBM, and Infosys, closely followed by Capgemini and Tata Consultancy Services (TCS). Indian heritage vendors occupy half of the top 10 vendor positions, suggesting they are successfully adapting their strategies to the long-term concern of a declining cost advantage versus their US and European peers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Clemizole Hydrochloride in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Clemizole Hydrochloride in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Clemizole Hydrochloride in Dravet Syndrome (Severe...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCART-123 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCART-123 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCART-123 in Refractory Acute Myeloid Leukemia Drug Details: UCART-123 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ampreloxetine Hydrochloride in Orthostatic Hypotension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ampreloxetine Hydrochloride in Orthostatic Hypotension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ampreloxetine Hydrochloride in Orthostatic Hypotension Drug Details: Ampreloxetine HCL (TD-9855) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCART-123 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCART-123 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCART-123 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-024 in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in Systemic Mastocytosis Drug Details: MGD-024 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-024 in Hairy Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in Hairy Cell Leukemia Drug Details: MGD-024 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCART-123 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCART-123 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCART-123 in Relapsed Acute Myeloid Leukemia Drug Details: UCART-123 is...